Montserrat Plana
Grup de recerca
- Sida i infecció per VIH Accredited researcher (R3A)
Publicacions destacades
-
Use of RT-defective HIV virions: new tool to evaluate specific response in infected individuals
Autors:Referència: Plos One 2013. -
In vitro effects of the CCR5 inhibitor maraviroc on human T cell function
Autors:Referència: Journal Of Antimicrobial Chemotherapy 2013. -
A dendritic cell-based vaccine elicits T cell responses associated with control 1 replication
Autors:Referència: Science Translational Medicine 2013. -
Therapeutic vaccines against HIV infection
Autors:Referència: Human Vaccines & Immunotherapeutics 2012. -
Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine
Autors:Referència: Vaccine 2009. -
Short Communication: Natural killer cells and expression of KIR receptors in chronic HIV type 1-infected patients after different strategies of structured therapy interruption
Autors:Referència: Aids Research And Human Retroviruses 2008. -
Redistribution of FOXP3-Positive regulatory T cells from lymphoid tissues to peripheral blood in HIV-Infected patients
Autors:Referència: Jaids-Journal Of Acquired Immune Deficiency Syndromes 2007. -
Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3
Autors:Referència: Jaids-Journal Of Acquired Immune Deficiency Syndromes 2004. -
Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3''A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression
Autors:Referència: Journal Of Infectious Diseases 2002. -
Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors
Autors:Referència: Jaids-Journal Of Acquired Immune Deficiency Syndromes 2002.
Projectes destacats
-
Red Temática de Investigación Cooperativa en Salud - SIDA (RIS)
Investigador/a principal: Felipe GarcíaFinançador: Instituto de Salud Carlos IIICodi: RD16/0025/0002Durada: 01/01/2017 - 31/12/2022 -
Evaluating a Combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection (HIVACAR)
Investigador/a principal: Felipe GarcíaFinançador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) (Sede o evento); European Comission. CE_H2020-SC1_16abr1sCodi: CE_H2020-SC1_16abr1sDurada: 02/01/2017 - 31/12/2021 -
FluNanoAir Design of Human Influenza vaccines using multifunctional micelles harnessing innate immunity
Investigador/a principal: Montserrat Plana IP from Partner 2 (FCRB / IDIBAPS)Finançador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); EuroNanoMed II JTC 2016Durada: 01/01/2017 - 31/12/2019 -
European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates
Investigador/a principal: Felipe Garcia Alcaide, Giuseppe Pantaleo Co-IPFinançador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) incluyendo 39 partners (Sede o evento); European Comunity's (H2020) Grant agreement n° 681032 ; European ComissionCodi: CE_H2020-PHCRTD-15Durada: 02/01/2016 - 31/12/2020 -
DESARROLLO DE UNA VACUNA TERAPÉUTICA FRENTE AL VIH BASADA EN UNA NUEVA FORMULACIÓN DE mRNA CON NANOPARTÍCULAS
Finançador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); FIS (Fondo de investigación Sanitaria; ISCIII) FIS PI15/00480Durada: 01/01/2016 - 01/01/2018